Effect of androgen deprivation therapy on bone mineral density in prostate cancer patients.
OBJECTIVE
To evaluate the effect of androgen deprivation therapy (ADT) on bone mineral density (BMD) in prostate cancer patients.


METHODS
Forty-nine prostate cancer patients with their BMD determined were divided into two groups: the non-treated group included 21 patients before the commencement of ADT and the treated group, 28 patients, who had received ADT for more than 1 year. BMD was measured by dual energy X-ray absorptiometry (DEXA) in the lumbar spine (L2-4) and femoral neck.


RESULTS
Thirteen (62 %) non-treated and 23 (82 %) treated patients fulfilled the BMD criteria for osteopenia or osteoporosis. Z scores for age-matched control in lumbar spine and femoral neck were -0.9 +/- 0.7 and -0.6 +/- 0.5, respectively, in the treated group, and -1.8 +/- 1.1 and -1.6 +/- 1.0, respectively, in the non-treated group, the differences between the two groups were highly significant (P<0.01).


CONCLUSIONS
Prostate cancer patients who received ADT for more than 1 year had a significantly lower BMD in the lumbar spine and femoral neck than those before the beginning of ADT.
Deng
Jun-Hong
JH
Department of Urology, First Municipal People's Hospital, Guangzhou 510180, China.
Yang
Liu-Ping
LP
Wang
Liang-Sheng
LS
Zhou
De-Fan
DF
D015502:Absorptiometry, Photon; D000368:Aged; D000369:Aged, 80 and over; D000728:Androgens / Q000172:deficiency; D015519:Bone Density; D001851:Bone Diseases, Metabolic / Q000175:diagnosis / Q000209:etiology*; D007987:Gonadotropin-Releasing Hormone / Q000627:therapeutic use; D006801:Humans; D008297:Male; D009919:Orchiectomy / Q000009:adverse effects*; D010024:Osteoporosis / Q000175:diagnosis / Q000209:etiology*; D011471:Prostatic Neoplasms / Q000628:therapy*
D000728:Androgens; D007987:Gonadotropin-Releasing Hormone